DV
Dividend Vision

STOK — Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. (STOK)

Total return is 22.3% over the past 7.2 years, 172.5 points behind SPY at 194.8%. Its deepest 1-year drawdown was 37.2%.

This appears to be a single-stock holding rather than a diversified ETF. Stoke Therapeutics is a biopharmaceutical company focused on RNA-based therapeutics, with no stated dividend distribution or yield profile. The holding is suitable for investors seeking exposure to the biotech sector, though it carries the concentration risk and volatility typical of individual equities rather than the diversification benefits of a traditional ETF.

STOK key facts

Asset type
Stock
Asset class
Equity
Inception date
06/19/2019
Distribution frequency
None
Last close
$31.27
Market cap
$2,017,735,552
Average volume
495100.0
Beta
1.228
Payout ratio
0.0
Forward P/E
204.0816
EPS
$-3.39